TickerFacts.

Company research / CUVL

Clinuvel Pharmaceuticals Ltd (CUVL)

Also trades as CLVLF. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001290877

For the year ended 2026-06-30, Clinuvel Pharmaceuticals Ltd reported revenue of $64.32M. Revenue grew 5.2% from the prior annual period.

Key ratios (year ended 2026-06-30)

82.9%
Gross margin
43.4%
Operating margin
36.0%
Net margin
12.3%
Return on year-end equity
5.2%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 20-F (annual report) · 2026-10-30

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2026-06-302025-06-302024-06-30
Revenue$64.32M$61.12M$57.91M
Cost of Revenue$10.98M$11.51M$10.74M
Gross Profit$53.34M$49.61M$47.17M
R&D Expense$12.23M$13.22M$9.99M
Operating Income$27.92M$26.52M$28.53M
Net Income$23.18M$23.12M$23.35M
EPS (Diluted)$0.46$0.46$0.46
Total Assets$203.98M$176.74Mn/a
Total Liabilities$15.36M$20.00Mn/a
Shareholders' Equity$188.62M$156.74M$135.03M
Cash & Equivalents$13.91M$18.06Mn/a
Operating Cash Flow$12.91M$27.30M$23.75M
Capital Expenditures$1.06M$190.6K$3.65M
Free Cash Flow$11.85M$27.10M$20.10M
Share Repurchasesn/a$174.0K$497.7K
Dividends Paid$1.67M$1.69M$1.59M
Shares Outstanding50.43M50.12Mn/a
Weighted Average Diluted Shares50.75M50.38M51.03M
EPS (Basic)$0.46$0.46$0.47